Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients

Unstable Angina Clinical Trial

Official title:

A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro®) Over a Period of 24 Hours

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01020383
• Other study ID #: ALX-0081-2.1/09
• Status: Completed
• Phase: Phase 2
• Start date: September 2009
• Est. completion date: March 2012

Study information

• Verified date: January 2019
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients. Patients will receive standard treatment with acetylsalicylic acid (ASA) plus clopidogrel and heparin. Eligible patients will be randomly assigned to receive open-label study treatment with either ALX-0081 or ReoPro®. Patients will be stratified according to PCI type (elective or ad-hoc) and stent type (bare metal stent or drug eluting stent).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 364
• Est. completion date: March 2012
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have unstable angina or NSTEMI,or stable angina with at least 2 factors indicating a high risk PCI as follows: patient related: diabetic patients, renal failure (glomerular filtration rate < 60), reduced left ventricular ejection fraction < 35%, age > 75 years, female gender and/or lesion/anatomy related: SYNTAX score > 26, bifurcation lesions, multi-vessel disease, intracoronary thrombus.
• Adequate hematological function including platelets > 100000/mm3.
• Body mass index (BMI) =18 kg/m2 and = 35 kg/m2.
• Aged = 18 years old.
• Women of childbearing potential must be practicing a medically acceptable contraceptive regimen. Only males who do not want to father children during the study and in the first 4 months after treatment may be included in the study. During this period, safe contraception is mandatory. Male patients who are sexually active must use a condom during intercourse and ensure that the female partner uses a reliable contraceptive method, or they must refrain from sexual intercourse during the first 4 months after treatment.
• Patients must be accessible for follow-up.
• Have a sufficient command to read and understand all instructions necessary for giving informed consent and participating in the study.
• Have signed and dated written informed consent prior to any study-related procedures.

Exclusion Criteria:

• Previous (within 30 days) treatment with GPIIb/IIIa inhibitors (such as ReoPro®).
• ST-elevation myocardial infarction (STEMI).
• Chronic total occlusion of a coronary artery.
• Scheduled rotablator procedure.
• PCI of the arterial or venous by-pass graft.
• Any contra-indication for ReoPro®.
• Major organ dysfunction, infection or any serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
• Known hypersensitivity to human/humanized antibodies.
• Women who are pregnant or lactating.
• Dementia or significantly altered mental status that would prohibit understanding the study procedures and giving informed consent.
• Use of vitamin K antagonists and/or Factor Xa inhibitors within 4 weeks prior to admission to the Hospital Intensive Care Unit.
• Use of GPIIa/IIIb inhibitors other than ReoPro®; prasugrel, bivalirudin and fondaparinux prior to and throughout the study.
• Known history of acquired or congenital bleeding disorder, coagulopathy or platelet disorder.
• Evidence of active pathological bleeding at screening or history of clinically significant bleeding (such as gastrointestinal or genitourinary) within the last 6 months prior to screening visit, unless the cause has been definitely corrected
• History of intracranial bleeding (e.g. hemorrhagic stroke, subdural hematoma, subarachnoid hemorrhage) or history of hemorrhagic retinopathy.
• History of ischemic stroke or TIA, within the past year prior to screening or known structural cerebral vascular lesion (e.g. arteriovenous malformation, aneurysm).
• History of New York Heart Association class III or IV congestive heart failure or history of severe, uncontrolled cardiac arrhythmias at screening.
• Planned elective surgical operation or major invasive procedures or traumas from 30 days prior to screening to completion of the study at Day 30 (the decision of what constitutes a major invasive procedure or trauma will be at the discretion of the investigator in conjunction with review and approval by the Medical Monitor).
• Use of another investigational drug or device within previous 30 days (12 weeks for investigational devices, e.g. unapproved stents) prior to screening.

Related Conditions & MeSH terms

• Angina Pectoris
• Angina, Stable
• Angina, Unstable
• Infarction
• Myocardial Infarction
• Non ST Segment Elevation Myocardial Infarction (NSTEMI)
• Stable Angina (Associated With High Risk PCI)
• Unstable Angina

Intervention

Drug:
• ALX-0081
4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
• ReoPro®
0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ablynx, a Sanofi company

Countries where clinical trial is conducted

Austria,  Belgium,  Czechia,  Germany,  Israel,  Poland,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and severity of bleeding classified by the following criteria: TIMI major bleeding events, TIMI minor bleeding events, bleeding events requiring medical attention, defined as TIMI minimal bleeding events		30 days